Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind and Placebo-controlled Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of KN056 in Healthy Participants

NCT05385575 is registered in ClinicalTrials.gov with Suzhou Alphamab Co., Ltd. as lead sponsor.

NCT NCT05385575
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05385575 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind and Placebo-controlled Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of KN056 in Healthy Participants
Lead sponsor
Suzhou Alphamab Co., Ltd.
Phase
Phase 1
Overall status
Completed
Start date
August 9, 2022
Completion date
February 29, 2024
Enrollment
46 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

type 2 diabetes